SET adds new listed securities : MEGA08C2209A to be traded on April 20, 2022
April 19, 2022 at 11:55 am
Share
Date/Time
19 Apr 2022 17:00:02
Headline
SET adds new listed securities : MEGA08C2209A to be traded on April 20, 2022
Symbol
MEGA08C2209A
Source
SET
Full Detailed News
Listing
Listing : Derivative warrant
DW issuer : ASIA PLUS SECURITIES COMPANY LIMITED
(ASPS)
DW symbol : MEGA08C2209A
Full DW name : DERIVATIVE CALL WARRANTS ON MEGA
LIFESCIENCES PUBLIC COMPANY LIMITED ISSUED BY ASIA PLUS SECURITIES COMPANY
LIMITED LAST TRADING IN SEPTEMBER 2022 # A
Secondary market : SET
Trading date : 20-Apr-2022
Number of DW (unit: DWs) : 60,000,000
Underlying Asset : MEGA LIFESCIENCES PUBLIC COMPANY
LIMITED (MEGA)
Issue price (Baht/Unit) : 1.00
DW Value (Baht) : 60,000,000.00
Exercise ratio (DW : Underlying Asset) : 14 : 1
Exercise ratio (Calculate) : 0.07143
Exercise price (Baht) : 66.00
Settlement price : Closing price of underlying asset on
last trading date
Type of DW : Call warrant
Exercise type : European style
Distribute date : 19-Jul-2022
Last trading date : 30-Sep-2022
Date of post "SP" sign : From 03-Oct-2022 to 05-Oct-2022
Maturity date : 05-Oct-2022
Last exercise date : 05-Oct-2022
Delisting date : 06-Oct-2022
Market maker : ASIA PLUS SECURITIES COMPANY LIMITED
(ASPS)
Settlement condition(s) : Cash settlement
Remark :
Please see Terms and Conditions of DW above-mentioned through PDF file
disseminated on the SET Market Analysis and Reporting Tool (SETSMART).
______________________________________________________________________
Attachments
Original Link
Original Document
Permalink
Disclaimer
Mega Lifesciences pcl published this content on 19 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 April 2022 10:53:02 UTC.
Mega Lifesciences Public Company Limited is engaged in manufacturing, marketing, selling and distributing quality pharmaceutical, nutraceutical products and Fast-Moving Consumer Goods (FMCG). Its segments include Maxxcare distribution business, Mega We Care branded products business, and original equipment manufacturer (OEM) business. The Maxxcare distribution business markets, sells and distributes various branded prescription pharmaceutical products, OTC and FMCG products. Its services include warehouse management, collections, including assuming the liability for bad debts, and value-added services. Its Mega We Care branded products business develops, manufactures, markets and sells its own brand of nutraceutical products, prescription pharmaceutical products and OTC products. Mega We Care branded products are sold in a total of 35 countries around the world. Its manufacturing facilities in Thailand and Australia accept various production orders from third-party customers.